Guidance for Industry on Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims
Extension without change of a currently approved collection
No
Regular
Approved without change
12/02/2013
09/10/2013
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
12/31/2016
36 Months From Approved
11/30/2013
21
0
71
410
0
14
0
0
0
This guidance is intended to assist applicants in developing labeling for outcome claims for drugs that are indicated to treat hypertension. The appropriate use of these drugs can be encouraged by making the connection between lower blood pressure and improved cardiovascular outcomes more explicit in labeling.
The requested burden hours for the 2010 ICR was 290 hours. ROCIS erroneously approved the total hours as 14 so the current total burden hours shows as 14 in ICRAS/ROCIS. Therefore, although ICRAS/ROCIS shows an increase in burden (from 14 to 410) the actual increase in burden is 290 to 410 (a difference of 120 hours) which results from an adjustment based on a review of the data we received on this ICR over the past few years.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.